The lung immune prognostic index (LIPI) has been postulated as a novel categorical hematological biological marker to select individuals diagnosed with NSCLC who are suitable candidates for PD-1/PD-L1 therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.